摘要
抗癌药研究开发是一个热点。本综述对美国知名医药信息机构Fierce Biotech推介的10个后期开发的抗癌药作简要介绍。其中多半安全性和疗效数据有竞争性,新药申请在即,或已经取得获准所需的肯定的后期试验数据;有些则是肿瘤药物开发新领域的代表。
The R&D of cancer drugs is a hot spot. In this review, top 10 late-stage cancer drugs recommended by Fierce Biotech are described. Most of them have competitive safety and efficacy data. New Drug Application (NDA) will be expected in 2012 or positive late-state trial data for approval will be available. Some of them are representative of an emerging area in cancer drug development.
出处
《上海医药》
CAS
2013年第3期55-60,共6页
Shanghai Medical & Pharmaceutical Journal